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Background: Obsessive-compulsive disorder (OCD) is a very disabling condition with a chronic course, if left
untreated. Though cognitive behavioral treatment (CBT) with or without selective serotonin reuptake inhibitors
(SSRI) is the method of choice, up to one third of individuals with obsessive-compulsive disorder (OCD) do not
respond to treatment in terms of at least 35% improvement of symptoms. Mindfulness based cognitive therapy
(MBCT) is an 8-week group program that could help OCD patients with no or only partial response to CBT to
reduce OC symptoms and develop a helpful attitude towards obsessions and compulsive urges.
Methods/design: This study is a prospective, bicentric, assessor-blinded, randomized, actively-controlled clinical
trial. 128 patients with primary diagnosis of OCD according to DSM-IV and no or only partial response to CBT will
be recruited from in- and outpatient services as well as online forums and the media. Patients will be randomized
to either an MBCT intervention group or to a psycho-educative coaching group (OCD-EP) as an active control
condition. All participants will undergo eight weekly sessions with a length of 120 minutes each of a structured
group program. We hypothesize that MBCT will be superior to OCD-EP in reducing obsessive-compulsive symptoms
as measured by the Yale-Brown-Obsessive-Compulsive Scale (Y-BOCS) following the intervention and at 6- and
12-months-follow-up. Secondary outcome measures include depressive symptoms, quality of life, metacognitive
beliefs, self-compassion, mindful awareness and approach-avoidance tendencies as measured by an approach
avoidance task.
Discussion: The results of this study will elucidate the benefits of MBCT for OCD patients who did not sufficiently
benefit from CBT. To our knowledge, this is the first randomized controlled study assessing the effects of MBCT on
symptom severity and associated parameters in OCD.
Trial registration: German Clinical Trials Register DRKS00004525. Registered 19 March 2013.
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Obsessive Compulsive Disorder (OCD) is a very disabling
condition and the fourth most common mental illness
with a lifetime prevalence of 1-3% and a 12-month-
prevalence of 1-2% [1]. Individuals with OCD experience
recurrent intrusive thoughts or impulses (obsessions) and/
or repetitive behaviors (compulsions). If left untreated,* Correspondence: anne.katrin.kuelz@uniklinik-freiburg.de
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unless otherwise stated.obsessive-compulsive disorder usually takes a relapsing
course and becomes chronic [2,3], associated with sub-
stantial impairment of quality of life [4,5] and limitations
in social and professional life [6]. Thus, the disorder
causes high costs, not only for the affected individuals but
also for their families, the health system and society (see
[7] for a review).
Cognitive Behavioral Therapy (CBT) with Exposure
and Response Prevention (ERP) and/or pharmacological
treatment with Selective Serotonin Reuptake Inhibitors
(SSRI) is the evidence-based treatment of choice for. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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post-effect-sizes of roughly Cohen’s d = 1.5 and controlled
effect sizes around 1.1 are reported [10]. The effectiveness
of CBT with ERP is yet limited by substantial rates of pa-
tients who do not or only partially respond, suffer relapses
or discontinue therapy. About thirty-five percent of the
patients do not respond to the treatment recommended
by current guidelines in terms of a reduction of symptom
severity of at least 35% [11-13]. In addition, the probability
of relapse over a 2-year period after achieving remission
has been found to be 48% [14]. Especially for the sub-
groups of patients who do not satisfactorily benefit from
CBT with ERP, complementary or alternative treatment
strategies must be developed.
Mindfulness-Based Cognitive Therapy (MBCT) [15] is a
manualized intervention program in an outpatient group
format consisting of eight sessions. It combines mindful-
ness exercises with elements of cognitive therapy and has
originally been designed to prevent relapse in depression.
As has been shown in randomized controlled trials of two
independent research groups, MBCT as an add-on to
treatment as usual (TAU) reduces the probability of re-
lapse in patients with three or more previous depressive
episodes when compared to TAU alone [16-18]. A re-
cently published study [19], however, found that MBCT
reduced risk of relapse compared with treatment as usual
only for participants who had experienced childhood
trauma. In a study using an uncontrolled design, MBCT
proved to be helpful in patients with acute depressive
symptoms: Significant symptom reductions with large ef-
fect sizes have been observed after the intervention [20].
In contrast, the findings of a small randomized controlled
study on MBCT in seasonal affective disorder suggest that
MBCT is not effective in the prevention of disorder recur-
rence [21]. Several research groups have adapted the ori-
ginal manual for patients with other psychiatric disorders.
According to current reviews, medium effect sizes for
MBCT in various disorders have been found [22,23]. In
randomized pilot studies, positive effects of MBCT have
been demonstrated in patients with panic disorder and
generalized anxiety disorder [24] and social phobia [25].
In patients with primary insomnia, symptom reductions
have been observed after a treatment combining mindful-
ness with elements of cognitive-behavioral interventions
in uncontrolled studies [26,27]. So far, however, no ran-
domized controlled study exists concerning the applica-
tion of MBCT in patients with OCD. This seems amazing,
since training of paying attention to the present moment
in an open, friendly and non-judgemental way as culti-
vated through mindfulness practice might be a powerful
way for OCD patients to deal with their intrusive, un-
wanted and often shaming thoughts and urges [28].
In line with this, several intervention studies hint at the
efficacy of mindfulness-skills in reducing OC-symptoms.In a controlled study on a student sample, subclinical OC
symptoms were observed to be significantly reduced after
a mindfulness training [29]. In the study by Kim and col-
leagues [24], in patients with generalized anxiety disorder
or panic disorder, a significant decrease on the OC-scale
of the Symptom Checklist-90-Revised (SCL-90-R), a self-
rating instrument assessing global psychopathology, was
observed. However, in this study, OC-symptoms have not
been assessed with more specific instruments targeting
OCD [24]. Some case studies also hint that mindfulness
might be useful for patients with OCD (e.g. [30]). In a re-
cent review, Bluett et al. [31] found that acceptance and
commitment therapy (ACT), a therapeutic approach fo-
cusing on mindfulness techniques and values, was equally
effective as manualized treatments such as cognitive be-
havioral therapy in OCD spectrum disorders.
To our best knowledge, manualized mindfulness inter-
ventions like MBCT and MBSR have not yet been inves-
tigated in controlled trials in patients with OCD at all.
Besides, there are no data on the long term effects of
mindfulness interventions in patients with OCD up to
now, though mindfulness might be a valuable adjunct to
CBT [32].
Based on these considerations, our workgroup recently
conducted an open pilot study on Mindfulness Based
Cognitive Therapy for patients with Obsessive Compul-
sive Disorder [33,34]. The intervention consisted in an
8-session MBCT program adapted to OCD [35] which
closely followed the original manual by Segal, Williams,
and Teasdale [15]. Qualitative and quantitative methods
were used, in order to both reflect the subjective experi-
ences of the participants with the treatment program
and, on the other hand, to examine objectifiable changes
in clinical symptoms. Twelve patients with residual OC
symptoms after CBT completed the program and were
examined immediately after the intervention and 6 months
later. The results showed that MBCT was feasible in pa-
tients with acute OCD and was well accepted by the par-
ticipants. From baseline to post assessment, a significant
reduction of the OC symptoms (p = .008) was observed
for the total scale of the Y-BOCS and the compulsions
subscale (p = .004) with effect sizes within the medium
range. Results remained stable at follow-up. We will there-
fore conduct a bicentric trial on a large sample to exa-
mine, for the first time, the effectiveness of MBCT
compared to a psychoeducative program (OCD-EP) in
OCD patients in order to control for unspecific group




The study design is shown in Figure 1. In a prospective,
bicentric, assessor-blinded, randomized, actively-controlled
Figure 1 Study design and measurement time points (CONSORT chart). AQ-10 = autism spectrum quotient short version; AAT = approach
avoidance task; BDI = Beck Depression Inventory II; BSI = Brief Symptom Inventory; KIMS = Kentucky Inventory of Mindfulness Skills; MBCT =Mindfulness
Based Cognitive Therapy; MCQ-30 =Metacognitions Questionnaire with 30 Items; WST = Test of Word Power; OBQ=Obsessive Beliefs Questionnaire;
OCD-EP =Obsessive Compulsive Disorder Education Program; OCI-R = Obsessive-Compulsive Inventory; SBQ-R = Suicidal Behaviors Questionnaire-
Revised; M.I.N.I Mini-International Neuropsychiatric Interview; INEP = Inventory of negative effects of psychotherapy; WHOQOL-BREF =World Health
Organization Quality of Life-BREF; Y-BOCS = Yale Brown Obsessive Compulsive Scale.
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criteria will be randomly assigned to one of two groups:
the studied intervention consists of 8 two-hour-sessions
of MBCT, the control condition consists of 8 two-hour-
sessions of OCD-EP. MBCT and OCD-EP will be compa-
rable regarding treatment setting.
In the proposed trial, we hypothesize that in patients
with OCD who are still symptomatic (i.e., Y-BOCS >12
points) after CBT, MBCT produces a significant reduc-
tion of OC symptoms from baseline to post assessment
compared to an OCD education program (OCD-EP). A
cutoff-score of 12 points is an established criterion of re-
mission proposed by Simpson et al. [11].
The long-term outcomes of MBCT and OCD-EP six
and twelve months after the interventions will be com-
pared in an explorative manner. Means, the rates of
treatment responders, the rates of patients who achieved
remission and the rates of patients who relapsed will be
compared. Treatment response and remission will be de-
fined according to the criteria by Jacobson and Truax
[36]. Their method includes the calculation of a) a cutofffor the symptom severity after the treatment, and b) an
index for a reliable symptom improvement (reliable
change index, RCI). Patients who fulfill both criteria
will be classified as remitted. Patients who fulfill criter-
ion b) will be classified as responders, even if their post-
treatment score is still above the cutoff. Relapse is defined
as a return to pre-treatment severity as recommended by
Simpson et al. [37]. Patients who were classified as remit-
ted after the intervention will be eligible for the analysis of
relapse rates [38].
Further exploratory research questions include the ef-
fects of MBCT on secondary outcome measures such as
comorbid depressive symptoms (as measured by the Beck
Depression Inventory), Quality of Life (World Health
Organization Quality of Life BREF), the general psycho-
pathology (Brief Symptom Inventory), the tendency to be
mindful in everyday life (Kentucky Inventory of Mindful-
ness Skills), distress tolerance (Distress Tolerance Scale),
self-compassion (Self-Compassion Scale) and dysfunc-
tional beliefs and attitudes (Obsessive Beliefs Question-
naire, Metacognitions Questionnaire). The relationship
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attitudes on the one hand and changes of clinical symp-
toms on the other hand will be addressed in exploratory
analyses. Possible negative effects of the MBCT and OCD-
EP treatment will also be explored. Additionally the change
in avoidance tendencies will be assessed using an approach
avoidance task (AAT) [39] measuring avoidance tendencies
to contamination and checking related words and pictures.
A subgroup of the sample will also take part in an add-
itional experience-sampling task to examine changes in
positive and negative affect, distress caused by OC symp-
toms, insight into the unreasonableness of obsessions as
well as acceptance of unpleasant feelings before and after
treatment. The experience sampling method (ESM) [40] is
characterised by the repeated collection of real-time data
on participants’ momentary inner states in their typical en-
vironments, thereby aiming to minimize memory biases
and ensuring ecological validity [41].
The interventions
Both interventions will consist of eight sessions with a
length of 120 minutes each, which will be held at weekly
intervals in an outpatient setting at the University Medical
Center of Freiburg and the University Medical Center
Hamburg. Each treatment group will consist of eight to
twelve participants.
MBCT is based on mindfulness training as developed
by Jon Kabat-Zinn at the University Medical Center of
Massachusetts, combined with psychoeducational ele-
ments from cognitive therapy. A detailed description of
the original intervention can be found in Segal, Williams
& Teasdale [15]. In the proposed trial, a modified version
of the manual will be applied: The mindfulness elements
are adopted from the original manual, and the cognitive
elements are tailored to patients with OCD [35].
We intend to use an education program as an active
control condition in order to control for unspecific ef-
fects of a group treatment. The program (OCD-EP) con-
sists of a presentation and education about the etiology,
mechanisms and maintaining factors of OC symptoms,
metacognitive and neurobiological perspectives on OCD,
information on existing pharmacotherapeutic and psycho-
logical treatment modalities and relapse prevention, group
sharing and discussion. Behavior therapy techniques or
mindfulness interventions are not part of the program.
The treatment sessions will be held by experienced be-
havioral therapists with longstanding experience in MBCT
respective psychoeducation of OCD.
Setting
Overall, eight MBCT- and eight OCD-EP-groups will be
conducted (four MBCT- und four OCD-EP-groups at each
site). The baseline assessments (T0) and post-assessments
(T1) will be performed directly before respectively after theinterventions. The first follow-up (T2) will be six months
and the second (T3) will be 12 months after the end of the
intervention.
The two participating centers will be the University
Medical Center Freiburg and the University Medical Cen-
ter Hamburg-Eppendorf. Both centers will recruit equal
proportions of participants. Potential distortions due to the
bicentric approach will be controlled by a stratification and
by homogeneous study conditions (same room equipment,
same training of the therapists, same measures, etc.).
The bicentric study was approved by the ethics commis-
sion of Freiburg University Medical Center. In accordance
with the Declaration of Helsinki, all participants will be in-
formed in detail about the design and purpose of the
study. Each participant will be required to sign a written
consent form and will have the freedom to withdraw con-
sent and quit the study at any point in time. Data will be
documented anonymously in a case report file (CRF),
which will be stored at the University Medical Center
Freiburg for 10 years. All necessary personal data will be
kept confidential. All sessions will be videotaped, super-
vised and checked for adherence. Supervision will be
provided by Prof. Thomas Heidenreich, University of
Esslingen.
Inclusion and exclusion criteria
The main inclusion criterion of our study is a primary
diagnosis of obsessive-compulsive disorder (ICD-10 F42.-).
Participants should suffer from clinically relevant OC
symptoms, i.e. a Y-BOCS global score >12 or subscore
of ≥8 in either obsessions or compulsions at study inclu-
sion. Participants are required to be between 18 and
70 years of age and to give informed consent. Since we aim
at testing the efficacy of MBCT for patients who are still
symptomatic after treatment, only patients who completed
at least 20 sessions of CBT with ERP prior to study inclu-
sion will be eligible.
The criteria are aiming at a preferably wide generaliz-
ability of the results. However, patients who require a
different treatment due to comorbid conditions or whose
condition gives reason to expect an inability to benefit
from a group treatment will be excluded from participa-
tion. These are patients with current manic episode or
manic episode within 5 years before study inclusion
(ICD-10 F30.-), patients with severe depressive episodes
according to ICD-10 criteria, a history of psychosis
(ICD-10 F20-F29), current substance dependence (ICD-
10 F1x.2), borderline personality disorder or Asperger
syndrome (ICD-10 F84.5). Further exclusion criteria are
suicidal tendencies according to the Suicidal Behaviors
Questionnaire-Revised (SBQ-R), severe neurological
disorders or an intelligence quotient <70 as measured
by the Test of Word Power (WST). Moreover, to pre-
vent confounding effects, patients with begun or altered
Külz et al. BMC Psychiatry 2014, 14:314 Page 5 of 9
http://www.biomedcentral.com/1471-244X/14/314psychotherapeutic treatment or medication within 12 weeks
before study inclusion are also excluded. A change of dos-
age within the same drug, however, is tolerated.
Sample size
A power analysis was performed with the program
“G*Power” [42]. Based on the pilot data, on results of
comparable studies [24,43] and on theoretical consider-
ations, we assume a between-group effect size of d = 0.5
favoring MBCT. Assuming an a priori test power of 0.8, a
total sample size of n = 128 (n = 64 per intervention) will
be sufficient to detect this effect by an F-test in an
ANOVA at p < .05 level of significance for a group × time-
point interaction. We assume a dropout rate of approx.
15% and thus target a total sample size of n = 148.
Outcome measures
Primary outcome
The Yale Brown Obsessive Compulsive Scale (Y-BOCS)
is a semi-structured clinical interview which is consid-
ered the gold standard for measuring OCD severity [44,45].
The Y-BOCS will be used as primary outcome in the pro-
posed trial.
Secondary outcomes
The Beck Depression Inventory-II (BDI) is a common
self-rating assessing the severity of depressive symptoms.
The instrument features good characteristics for internal
consistency, test-retest reliability and validity [46]. The
subjective quality of life will be measured by the World
Health Organization Quality of Life–abbreviated (WHO-
QOL-BREF), an interculturally valid, multidimensional
questionnaire with good to excellent psychometric prop-
erties [47]. The 18-item version of the Brief Symptom
Inventory (BSI) is a short, reliable and valid self-assessment
instrument for general psychopathology [48]. The 20-item-
version of the Kentucky Inventory of Mindfulness Skills
(KIMS) will be used to measure dispositional mindfulness
[49]. The instrument has good discriminant and conver-
gent validity and is sensitive to changes over the course of
MBCT [50]. The Obsessive-Compulsive Inventory Revised
(OCI-R) is a self-rating scale assessing the major symptoms
of OCD on six dimensions (see [51] for the German ver-
sion). The Obsessive Beliefs Questionnaire (OBQ) is a
multidimensional instrument assessing dysfunctional meta-
cognitive beliefs in the context of OCD. The questionnaire
has shown a satisfactory reliability and validity (see [52]
for the German version) and is sensitive to therapeutic
changes [53]. In addition to the OBQ, the short form of
the Metacognitions Questionnaire (MCQ-30) will be used.
The MCQ-30 is a brief questionnaire with good indices for
reliability and validity [54]. The instrument’s sensitivity to
therapeutic changes has been shown for the long version
[55]. The Distress Tolerance Scale (DTS) [56] measuresthe capacity to experience and withstand negative psycho-
logical states. As a German version of the instrument is not
yet available, the DTS was translated by our workgroup.
Moreover, the self- compassion scale (SCS) measures the
capability of cultivating self-kindness, common humanity
and mindfulness even when things go bad instead of self-
judgment, feelings of isolation and over-identification (see
[57] for the German version).
Diagnoses will be made by trained staff using the Mini
International Neuropsychiatric Interview (M.I.N.I.). The
M.I.N.I. is a structured diagnostic interview for DSM-IV
and ICD-10 psychiatric disorders [58]. The Suicidal Be-
haviors Questionnaire-Revised (SBQ-R) [59] and the
Test of Word Power (WST), which is a short, valid in-
strument assessing general intelligence [60] will be ad-
ministered at baseline. Besides, the Autism Spectrum
Quotient (AQ) [61] will be applied at baseline for assess-
ment of autistic traits. In addition, sociodemographic
variables and a questionnaire concerning satisfaction
with the result of randomization and motivation, con-
structed by the workgroup will be administered. The
medication status will be enquired and documented at
all times of assessment. Subjective treatment satisfaction
will be assessed after the program by the Treatment
Satisfaction Questionnaire (ZUF-8). Moreover, a ques-
tionnaire called “Side-Effects of Psychotherapy” scale
(SEPS), based on items of the Inventory of Negative Effects
of Psychotherapy (INEP) [62], a scale assessing negative ef-
fects of psychotherapy in different areas of life, as well as
items constructed by the workgroup assessing negative
outcomes of the intervention, will be administered post
treatment and follow-up. At both follow-ups, participants
will be asked about significant life events within the follow-
up period.
In addition, an approach-avoidance-task (AAT) [39], a
computerized neuropsychological paradigm, will be ap-
plied by comparing response times for OCD-related
(checking and contamination) and neutral words and
pictures, before and after treatment. In this task, patients
are instructed to respond to each stimulus presented on
the computer screen by pushing or pulling a joystick.
When participants push the joystick away from them-
selves, the picture on the screen shrinks, creating the
visual impression that the stimulus moves away. When
they pull the joystick, the picture grows until it fills the
screen, creating the impression of an approaching stimu-
lus. Response times for pulling and pushing stimuli away
can be compared in order to assess automatic avoidance
tendencies. A similar version of the AAT used in the
present study has already been applied in another study
on OCD patients [63].
Moreover, in order to investigate the participants’ expe-
riences in situ as an additional outcome measure of
MBCT and to gain further insight into the relationship of
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Method (ESM) [40] will be applied to a subset of the study
sample before and after treatment. Participants will be
asked to record their OC symptoms, the distress caused
by symptoms, affective states and acceptance of unpleas-
ant affective states respectively on an electronic device 6
times a day on 6 consecutive days before and after the
group interventions. The prompts to fill out a form will be
given at random time-points between 8 am and 22 pm
by the web-based experience sampling software movi-
sensXS (movisens GmbH, Karlsruhe). Partici\pants who
decide to take part in this additional paradigm will receive
50€ for compliance rates of at least 80% and a short sum-
mary of their mood profile and symptoms before and after
treatment.Statistical analyses
Between-group comparisons at baseline will be performed
using analyses of variance for the continuous variables
and Fisher’s exact test for the categorical variables. Means
and standard deviations will be calculated for descriptive
purposes. The main analyses will be computed using ana-
lyses of covariance in view of statistical studies suggesting
that controlling for the baseline score is superior to simple
pre-post comparisons and usually leads to an increase in
power. An advantage of this type of analysis over mixed
models is that it accounts for baseline differences and re-
gression to the mean (i.e. higher scores usually yield
greater improvement). The rates of patients achieving re-
sponse and/or remission and the relapse rates in both
groups will be compared using Fisher’s exact test. The
time to relapse will be estimated using Kaplan-Maier sur-
vival analyses. Survival curves will be compared using a
log-rank-test. A cox-regression will be performed to
analyze variables influencing the time to relapse. In order
to prevent distortions, the intent-to-treat principle will be
used. Multiple imputation will be adopted to estimate
post-treatment and follow-up scores for non-completers
(i.e. no data available at reassessment). The multiple im-
putation principle is considered superior to the last obser-
vation carried forward method (LOCF) [64]. When using
the LOCF, follow-up data can be difficult to interpret [10].Discussion
To the best of our knowledge, this is the first study to
evaluate the efficacy of MBCT in patients with OCD as
a complement to CBT with ERP. Based on the results of
the pilot study outlined above, the proposed project aims
at systematically examining the impact of MBCT as a
new treatment option for patients with OCD who do
not sufficiently benefit from CBT with ERP, who suffer a
relapse or who experience difficulties in partaking in this
kind of treatment.We also intend to undertake a wide range of additional
analyses. Various factors have been discussed that could,
individually or in their combination, mediate positive ef-
fects of mindfulness training in patients with OCD. One
of them is an increased willingness to experience diffi-
cult thoughts, feelings and body sensations [32]. A study
on patients with Social Phobia provided evidence that
Mindfulness Based Stress Reduction, a therapy program
that is closely linked to MBCT, improves emotion regu-
lation skills in patients with social phobia [65]. This
could be especially relevant for patients with OCD, be-
cause emotion regulation has been identified as a com-
mon function of OC symptoms [66]. We therefore will
examine changes of distress tolerance and their associ-
ation with therapeutic outcome. Moreover, the mindful-
ness approach might be helpful to question metacognitive
styles and beliefs that maintain OCD such as thought-
action fusion (TAF) [67,68] and thought control [69].
Thus, we will use measures of dysfunctional metacogni-
tions and believes in explanatory analysis in order to iden-
tify factors that mediate or moderate therapeutic effects.
Besides, we will evaluate the impact of self-compassion on
changes of symptom severity. Self-compassion has shown
to be below average in OCD patients [70] and was a better
predictor of symptom severity and quality of life than
mindfulness in patients with depression and anxiety
disorder [71]. Especially for patients with OCD, self-
compassion could be helpful to disengage from strug-
gling with shaming obsessions such as violent or sexual
intrusions and to deal with them in an accepting, not self-
judging manner. Furthermore, subgroup analyses on the
influence of baseline characteristics, such as baseline se-
verity, sociodemographic variables, comorbid mental dis-
orders and treatment motivation are planned.
We will further examine approach avoidance tenden-
cies as measured by the AAT, because patients struggle
to change their obsessions and compulsions even though
they have insight into the irrationality of their fears. Ac-
cording to 2-systems models, (e.g. [72]) behavior is influ-
enced by an automatic, inflexible impulsive system and a
slower and more flexible reflective system. In OCD it is
assumed that in the impulsive system, strong connec-
tions between obsessive related concepts and items are
associated with danger [73]. Therefore the AAT offers us
a chance to detect changes in behavioral tendencies that
patients may not be able to report.
There is a growing body of empirical evidence showing
that mindfulness-based interventions are effective in in-
creasing positive and/or in decreasing negative affect in
a variety of clinical conditions [74-77]. Since there is no
study exploring changes in positive and negative affect
caused by MBCT in OCD patients so far, we decided to
use the ESM paradigm in order to fill this gap and to
provide further insight into the nature of OC symptoms
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natural environments of participants.
Regarding recruitment of participants, we decided to
not exclude patients who currently undergo psychophar-
macological or psychotherapeutic treatment. One reason
for the liberal acceptance of concomitant treatments re-
fers to practical considerations. We assume to reduce
the non-eligibility rate and to improve external validity,
since the vast majority of patients with clinically relevant
OCD receive some kind of treatment. Another reason is
the chance to conduct subgroup analyses in order to
evaluate the efficacy of MBCT in patients with OCD as
a complement to current treatment. However, the ac-
ceptance of concomitant treatment may also constitute a
limitation of the study, since the power to detect a dif-
ference between MBCT and OCD-EP might be reduced
due to effects of other treatment modalities.
Finally, we hope that the 6-month and the 12-month
follow-up data will provide important insights in longterm-
effects of mindfulness-based interventions in OCD on se-
verity of symptoms and related measures such as obses-
sional beliefs or quality of life.
In view of the large percentage of OCD patients who
do not sufficiently benefit from conventional CBT with
stimulus exposure and response prevention, there is a
strong urge to find additional or complementary treat-
ment options. The present study wants to shed light on
the role of MBCT as a valuable intervention to boost the
gains from cognitive-behavioral approaches in OCD by
opening up new avenues of relating to OC symptoms.
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